OpenAI CEO Sam Altman among investors in embryo gene-editing venture
San Francisco-based startup Preventive has raised nearly $30 million from investors, including OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong, to develop embryo gene-editing technology aimed at preventing hereditary diseases.




















